Needham Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10

Benzinga · 10/02/2025 14:51
Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $8 to $10.